Latest News Archives - Page 5 of 8 - Targeting Phage Therapy Congress

Programmed M13 Bacteriophage Inspired Nose

Posted on February 24, 2022January 23, 2023 by Targeting Phage Therapy

Based on the programable surface chemistry of M13 bacteriophage and inspired by the neural mechanism of the mammalian olfactory system, Lee et al., proposed an electronic nose. The neural pattern separation (NPS) was devised to apply the pattern separation that operates in the memory and learning process of the brain to the electronic nose. This…

Phage Therapy Against SARS-Cov-2

Posted on February 24, 2022August 16, 2022 by Targeting Phage Therapy

Non-tailed phages with multifaceted capsid morphology (Cystoviridae, Leviviridae, Corticoviridae, Tectiviridae) and pleomorphic phages (Plasmaviridae). Knowing that one of the life threatening aspects of COVID-19 is secondary infections and reduced efficacy of antibiotics against them, Shahin et. al, brilliantly discussed the potential applications of bacteriophages in the fight against the present pandemic and the post-COVID era.…

Phage infection mediates inhibition of bystander bacteria

Posted on June 18, 2020February 25, 2022 by Targeting Phage Therapy

Phage infection mediates inhibition of bystander bacteria Bacteriophages (phages) are being considered as alternative therapeutics for the treatment of multidrug resistant bacterial infections. Considering phages have narrow host-ranges, it is generally accepted that therapeutic phages will have a marginal impact on non-target bacteria. We have discovered that lytic phage infection induces transcription of type VIIb…

Scientists hope to fight antibiotic-resistant bacteria by targeting their ‘alarm proteins’

Posted on December 12, 2019February 25, 2022 by Targeting Phage Therapy

© Pete Wardell/USCDCP/Pixnio For years, antibiotic-resistant infections have been the bane of modern health care. Now, researchers have found a new way to attack some types of these nearly unstoppable microbes, Wired reports. In a study published this week in the Proceedings of the National Academy of Sciences, researchers identified a special alarm protein in…

Microbiota Quality and Mitochondrial Activity Link with Occurrence of Muscle Cramps in Hemodialysis Patients

Posted on April 25, 2019February 25, 2022 by Targeting Phage Therapy

Pilote study on Microbiota Quality and Mitochondrial Activity by Pierre-Yves Durand, Carole Nicco, Dedier Serteyn, David Attaf, Marvin Edeas BACKGROUND/AIMS: Hemodialysis-associated muscle cramp (HAMC) is a common complication under citrate dialysate (CD) occurring in 30% of cases. Our objectives were to assess the gut microbiota quality, mitochondrial activity, and to investigate their possible relationship with…

Prof. Marvin Edeas highlights: Microbiota and Phage Therapy – “Future Challenges in Medicine”

Posted on April 25, 2019April 29, 2019 by Targeting Phage Therapy

Dr. Armelle Paule, Prof.Dominico Frezza and Prof. Marvin Edeas published an article on Phage Therapy and Microbiota. An imbalance of bacterial quantity and quality of gut microbiota has been linked to several pathologies. New strategies of microbiota manipulation have been developed such as fecal microbiota transplantation (FMT); the use of pre/probiotics; an appropriate diet;…

Non-antibiotic antimicrobial triclosan induces multiple antibiotic resistance through genetic mutation

Posted on June 29, 2018June 29, 2018 by Targeting Phage Therapy

Image from: Sciencedirect.com Mutations led to resistance by up-regulating beta-lactamase and multi-drug efflux pump. Antibiotic resistance poses a major threat to public health. Overuse and misuse of antibiotics are generally recognized as the key factors contributing to antibiotic resistance. However, whether non-antibiotic, anti-microbial (NAAM) chemicals can directly induce antibiotic resistance is unclear. We aim to…

Targeting Phage & Antibiotic Resistance World Congress 2018 concluding remarks

Posted on May 22, 2018April 3, 2024 by Targeting Phage Therapy

The 5th World Congress on Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance 2018 was organized in Florence, Italy in May 17-18, 2018. During two days, more than 100 oral & poster communications were highlighted different axes and topics related to the recent advances and challenges in phage therapy, and to all innovations related to…

The poster contribution awards were delivered to two young researchers

Posted on May 22, 2018April 3, 2024 by Targeting Phage Therapy

During Phage Therapy & Antibiotic Resistance Congress 2018, Dr Thomas Thompson from Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom presented a poster about “Halophiles a novel source of antimicrobial natural products”. The aim of this study was “to establish the potential of extremely halophilic microorganisms from Kilroot Salt Mine, Northern Ireland, as a…

Efficient in vivo phage therapy via immunological cloaking awarded for the best short oral presentation

Posted on May 22, 2018April 3, 2024 by Targeting Phage Therapy

Dr Yoon Sung Nam from the Korea Advanced Institute of Science and Technology at Daejeon, Republic of Korea was awarded for his short oral presentation about “Efficient in vivo phage therapy via immunological cloaking” during Phage Therapy & Antibiotic Resistance Congress 2018. The aim of Dr Nam’s study was to “immunologically cloaked T7 phage…